We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact us so we can address the problem.
Clinical significance of circulatory chlamydial heat shock protein-60 antibodies in spondyloarthropathy patients
© Kumar et al; licensee BioMed Central Ltd. 2014
- Published: 27 May 2014
- Rheumatoid Arthritis
- Case Control Study
- Disease Duration
- Chlamydia Trachomatis
Chlamydia trachomatis is a multifaceted, asymptomatic, most prevalent sexually transmitted pathogen worldwide. Due to lack of specific diagnostic methods for C. trachomatis in Spondyloarthropathy (SpA) patients, this pathogen is under diagnosed and under estimated in various countries including India. We aimed to estimate circulatory antibodies to chlamydial heat shock protein-60 (chsp60) IgG/ anti C. trachomatis IgA and evaluate their clinical significance in SpA patients.
In this case control study, serum from 60 arthritic patients comprising of Reactive Arthritis (ReA), undifferentiated SpA, Rheumatoid Arthritis (RA) and Osteoarthritis (OA) was collected for detection of anti chsp60 IgG and anti C. trachomatis IgA antibodies by using commercial ELISA kits. Cut-off indices (COI) of infected SpA patients were correlated with clinical data.
Overall, 12/ 30 (40.0%) SpA patients, viz.: ReA/uSpA, were found positive for either circulatory chsp60 IgG or anti C. trachomatis IgA antibody (p value < 0.009 versus RA/ OA). 23.3% (7/ 30) SpA patients and 3.3 % (1/30) RA/OA control patients were found to be positive for circulatory chsp60 IgG antibodies. 16.6% (5/ 30) patients found positive for anti C. trachomatis IgA antibodies; however, none of the controls was infected. COI, age and disease duration in chsp60-positive SpA patients showed significant difference in median values (Kruskal-Wallis test; p value < 0.0001) while there was no such relation to anti C. trachomatis IgA.
Overall findings indicate an active/chronic C. trachomatis infection in SpA patients. The study also suggests usefulness of chsp60 serology to facilitate better clinical management of patients.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.